We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Nears Decision on First Follow-On Biologic
EMEA Nears Decision on First Follow-On Biologic
March 17, 2006
The European Medicines Agency (EMEA) is nearing a decision on whether to approve Sandoz’ generic biologic Omnitrope and Swiss firm BioPartners’ follow-on product Valtropin, experts familiar with the issue told WDL.